IDO was implicated as a potential host factor that increases susceptibility to secondary lung infections as mice treated with IDO inhibitor following primary influenza infection exhibited more effective control of subsequent pneumococcal infections, though increased host control of secondary infections did not translate into lower mortality in this co-infection model [6]. The gene discussed is IDO1; the disease is pneumococcal infection.